MITI-101
Alzheimer's Disease
PreclinicalActive
Key Facts
About MindImmune Therapeutics
MindImmune Therapeutics is a private, preclinical-stage biotech founded in 2018 and headquartered in San Diego, CA. The company is pioneering an immunomodulatory approach to neurodegenerative diseases, with an initial focus on Alzheimer's disease. Its core technology involves targeting a specific innate immune cell recruited into the brain that drives damaging neuroinflammation. The company is advancing its lead candidate, MITI-101, towards an IND, supported by a $30M Series A financing round and a leadership team with extensive CNS drug discovery experience.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |